The startup develops proprietary regenerative therapeutics that combine pharmacological treatments with psychotherapy to enhance the efficacy of interventions for affective disorders, chronic pain, and insomnia. Their formulations target neurodegenerative conditions, providing medical professionals with a dual approach to improve patient outcomes.
Funding
$11.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for affective disorders, chronic pain, and insomnia often have limited efficacy, leaving a significant number of patients without adequate relief. Existing pharmacological and psychotherapeutic interventions may not fully address the underlying neurobiological and psychological factors contributing to these conditions. This can result in prolonged suffering and reduced quality of life for affected individuals.
Solution
Reconnect Labs develops integrated therapeutic approaches combining pharmacological treatments with targeted psychotherapy to improve outcomes for individuals with affective disorders, chronic pain, and insomnia. Their approach focuses on enhancing the brain's natural regenerative capabilities to promote healing and resilience. By integrating pharmacological interventions with evidence-based psychotherapeutic techniques, Reconnect Labs aims to address both the biological and psychological dimensions of these complex conditions, offering medical professionals a comprehensive strategy to improve patient well-being and long-term outcomes. The company supports academic research on consciousness, healthcare accessibility, and Indigenous stewardship of ecosystems and biodiversity.
Target Audience
The primary target audience includes medical professionals, such as psychiatrists, pain specialists, and therapists, seeking innovative and integrated treatment options for patients with affective disorders, chronic pain, and insomnia.
Features
- Proprietary formulations designed to target neurodegenerative processes associated with affective disorders, chronic pain, and insomnia
- Integration of pharmacological treatments with psychotherapy to enhance therapeutic efficacy
- Focus on promoting the brain's natural regenerative capabilities
- Support for academic research on consciousness
- Support for healthcare accessibility programs
- Support for Indigenous stewardship of ecosystems and biodiversity